Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Cardiology

Evaluating Risk: Sudden Cardiac Death and the Role of ICDs

At a Glance

While sudden cardiac death is rare in hypertrophic cardiomyopathy, doctors use specific risk factors to identify vulnerable patients. If you have extreme heart thickening, extensive MRI scarring, or a family history of sudden death, your doctor may recommend an implantable defibrillator (ICD).

For many people diagnosed with Hypertrophic Cardiomyopathy (HCM), the most significant concern is the risk of Sudden Cardiac Death (SCD). While this is a serious topic, it is important to lead with the facts: SCD is rare in the HCM community, and modern medicine has become exceptionally good at identifying who is at risk and how to protect them [1][2].

The Modern Approach to Risk

Cardiologists use a process called risk stratification to determine the likelihood of a life-threatening heart rhythm [3]. According to the latest 2024 AHA/ACC Guidelines, doctors look for specific “markers” in your health history and imaging that might suggest a higher risk [1][4].

Instead of a single test, your doctor will piece together a “risk profile” based on several key factors:

1. Massive Heart Muscle Thickening

If the thickest part of your heart wall (Maximum Left Ventricular Wall Thickness) is 30 millimeters (mm) or greater, this is considered a major risk factor [5][1].

2. Family History of Sudden Death

A major risk factor is having a first-degree relative (parent, sibling, or child) who died suddenly and unexpectedly from HCM, especially if it happened before the age of 50 [6][7].

3. Unexplained Fainting (Syncope)

Fainting that cannot be explained by dehydration or simple lightheadedness is a significant warning sign, especially if it occurs during or shortly after physical activity [6][8].

4. Findings on Cardiac MRI

Modern imaging has added two critical markers to the risk list:

  • Extensive Late Gadolinium Enhancement (LGE): This is a measure of scarring (fibrosis) in the heart. While there is no single “magic number,” extensive scarring (often defined as 15% or more of the heart muscle) is a known risk marker [9][10][11].
  • LV Apical Aneurysm: This is a small “pouch” or thinning at the tip of the heart. If found, it can be a source of dangerous heart rhythms and is a strong reason to consider extra protection [12][13].

5. Irregular Rhythms (NSVT)

If a heart monitor (Holter monitor) picks up short bursts of a rapid heart rhythm called Non-Sustained Ventricular Tachycardia (NSVT), your doctor will factor this into your overall risk, especially if the bursts are frequent or very fast [14][15].

The Role of the ICD

If your risk profile suggests you are at a higher-than-average risk for SCD, your doctor will likely recommend an Implantable Cardioverter-Defibrillator (ICD).

An ICD is a small device placed under the skin that acts like a “personal paramedic.” It constantly monitors your heart rhythm 24/7. If it detects a life-threatening, rapid rhythm, it can deliver a localized electric shock to “reset” the heart and save your life [16][17].

Primary vs. Secondary Prevention

  • Primary Prevention: This is when an ICD is placed before a dangerous event has ever happened, based solely on your risk factors [17][18].
  • Secondary Prevention: This is when an ICD is placed because you have already survived a cardiac arrest or a dangerous heart rhythm [18].

Shared Decision-Making and Daily Life

Deciding to get an ICD is a significant step. Current guidelines emphasize shared decision-making, where you and your doctor weigh the life-saving benefits against the potential for complications, such as “inappropriate shocks” or device-related issues [19][20].

Important Note on Driving: Experiencing an unexplained fainting spell (syncope) or receiving an appropriate shock from an ICD will typically result in temporary restrictions on your driving privileges to ensure your safety and the safety of others [18]. Your values, lifestyle, and personal comfort level are just as important as the clinical numbers when discussing ICD placement with your doctor [21].

Return to Home

Common questions in this guide

How do doctors determine if I am at risk for sudden cardiac death with HCM?
Cardiologists use risk stratification to build a profile based on your health history and imaging. They look for major markers like a family history of sudden death, unexplained fainting, extreme heart muscle thickness, and specific patterns of scarring on a cardiac MRI.
What does a wall thickness of 30mm mean for my HCM risk?
A maximum left ventricular wall thickness of 30 millimeters or greater is considered massive thickening. According to modern guidelines, this is a major risk factor that increases the likelihood of dangerous heart rhythms.
How does a cardiac MRI help assess my risk in HCM?
A cardiac MRI can reveal critical risk markers that other tests might miss. It specifically looks for extensive scarring, known as Late Gadolinium Enhancement (LGE), and structural abnormalities like an apical aneurysm at the tip of the heart.
What is the purpose of an ICD for hypertrophic cardiomyopathy?
An Implantable Cardioverter-Defibrillator (ICD) is a small device that monitors your heart rhythm continuously. If it detects a life-threatening, rapid heartbeat, it delivers a localized electric shock to restore a normal rhythm and prevent sudden cardiac arrest.
Will I still be able to drive if I have unexplained fainting or an ICD shock?
Experiencing an unexplained fainting spell or receiving an appropriate shock from your ICD usually results in temporary driving restrictions. This is a standard medical safety precaution to protect both you and other drivers on the road.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the 2024 AHA/ACC guidelines, how many 'major' risk factors for sudden cardiac death do I currently have?
  2. 2.Does my Cardiac MRI show an 'apical aneurysm' or 'extensive LGE,' and how do these specific findings change my risk level?
  3. 3.What is my maximum wall thickness, and does it reach the 'massive' threshold of 30mm?
  4. 4.If we decide on an ICD, what are the pros and cons of a 'transvenous' (through the vein) versus a 'subcutaneous' (under the skin) device for me?
  5. 5.How often should we repeat my 24-48 hour heart monitor (Holter) and Cardiac MRI to re-evaluate my risk over time?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

    Ommen SR, Ho CY, Asif IM, et al.

    Circulation 2024; (149(23)):e1239-e1311 doi:10.1161/CIR.0000000000001250.

    PMID: 38718139
  2. 2

    Frequency of misdiagnosis in hypertrophic cardiomyopathy.

    Nielsen SK, Rasmussen TB, Hey TM, et al.

    European heart journal. Quality of care & clinical outcomes 2025; (11(2)):105-112 doi:10.1093/ehjqcco/qcae031.

    PMID: 38664062
  3. 3

    Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy Across the Lifespan: Reconciling the American and European Approaches.

    Al Samarraie A, Petzl A, Cadrin-Tourigny J, Tadros R

    Heart failure clinics 2025; (21(4)):599-610 doi:10.1016/j.hfc.2025.07.002.

    PMID: 41077657
  4. 4

    2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

    , Ommen SR, Ho CY, et al.

    Journal of the American College of Cardiology 2024; (83(23)):2324-2405 doi:10.1016/j.jacc.2024.02.014.

    PMID: 38727647
  5. 5

    Rethinking Risk in Hypertrophic Cardiomyopathy: Assessing the Role of Myocardial Fibrosis and Left Ventricular Hypertrophy in Sudden Cardiac Death.

    Badr A, Farina J, Arsanjani R, et al.

    Mayo Clinic proceedings. Innovations, quality & outcomes 2024; (8(6)):517-520 doi:10.1016/j.mayocpiqo.2024.09.001.

    PMID: 39958455
  6. 6

    Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy.

    Santoro F, Mango F, Mallardi A, et al.

    Journal of clinical medicine 2023; (12(10)) doi:10.3390/jcm12103397.

    PMID: 37240503
  7. 7

    Family History of Sudden Death Should Be a Primary Indication for Implantable Cardioverter Defibrillator in Hypertrophic Cardiomyopathy.

    Maron MS

    The Canadian journal of cardiology 2015; (31(11)):1402-6.

    PMID: 26239004
  8. 8

    The Risk of Sudden Death in Children with Hypertrophic Cardiomyopathy.

    Norrish G, Kaski JP

    Heart failure clinics 2022; (18(1)):9-18 doi:10.1016/j.hfc.2021.07.012.

    PMID: 34776087
  9. 9

    Serial Myocardial Fibrosis Assessments Predict Outcomes in Patients With Hypertrophic Cardiomyopathy.

    Tang Y, Chen X, Zhao K, et al.

    JACC. Cardiovascular imaging 2026; (19(6)):688-701 doi:10.1016/j.jcmg.2026.01.008.

    PMID: 41706079
  10. 10

    Left ventricular involvement assessed by LGE-CMR in predicting the risk of adverse outcomes of arrhythmogenic cardiomyopathy with ICDs.

    Zhang N, Song Y, Hua W, et al.

    International journal of cardiology 2021; (337()):79-85 doi:10.1016/j.ijcard.2021.04.015.

    PMID: 33839174
  11. 11

    The incremental role of late gadolinium enhancement in risk stratifying high risk patients with hypertrophic cardiomyopathy.

    Ravi SN, O'Shea M, Baqal O, et al.

    American heart journal 2025; (289()):28-37 doi:10.1016/j.ahj.2025.04.030.

    PMID: 40324572
  12. 12

    Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis.

    Papanastasiou CA, Zegkos T, Karamitsos TD, et al.

    International journal of cardiology 2021; (332()):127-132 doi:10.1016/j.ijcard.2021.03.056.

    PMID: 33794232
  13. 13

    What Is the Significance of Greater Global Wasted Work in Patients With Apical Hypertrophic Cardiomyopathy and Apical Aneurysm? Is It the Chicken or the Egg?

    Pollick C

    Echocardiography (Mount Kisco, N.Y.) 2024; (41(10)):e70010 doi:10.1111/echo.70010.

    PMID: 39427306
  14. 14

    Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy.

    Wang W, Lian Z, Rowin EJ, et al.

    Circulation. Arrhythmia and electrophysiology 2017; (10(3)) doi:10.1161/CIRCEP.116.004604.

    PMID: 28314849
  15. 15

    The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.

    Weissler-Snir A, Hindieh W, Spears DA, et al.

    Journal of cardiovascular electrophysiology 2019; (30(5)):651-657 doi:10.1111/jce.13855.

    PMID: 30680853
  16. 16

    Evidence That Subcutaneous Implantable Cardioverter-Defibrillators Are Effective and Reliable in Hypertrophic Cardiomyopathy.

    Maron MS, Steiger N, Burrows A, et al.

    JACC. Clinical electrophysiology 2020; (6(8)):1019-1021 doi:10.1016/j.jacep.2020.03.015.

    PMID: 32819515
  17. 17

    The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy.

    Maron MS, Rowin EJ, Maron BJ

    The American journal of cardiology 2024; (212S()):S64-S76 doi:10.1016/j.amjcard.2023.10.076.

    PMID: 38368038
  18. 18

    Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.

    Maron BJ, Rowin EJ, Casey SA, et al.

    Circulation 2016; (133(1)):62-73 doi:10.1161/CIRCULATIONAHA.115.017633.

    PMID: 26518766
  19. 19

    Predicting the Future in Hypertrophic Cardiomyopathy.

    Ho CY, Link MS

    Circulation 2018; (137(10)):1024-1026 doi:10.1161/CIRCULATIONAHA.117.032627.

    PMID: 29506995
  20. 20

    Development and piloting of four decision aids for implantable cardioverter-defibrillators in different media formats.

    Wallace BC, Jones J, Masoudi FA, et al.

    Pacing and clinical electrophysiology : PACE 2021; (44(11)):1842-1852 doi:10.1111/pace.14365.

    PMID: 34528271
  21. 21

    Experiences Implementing a Suite of Decision Aids for Implantable Cardioverter Defibrillators: Qualitative Insights From the DECIDE-ICD Trial.

    Knoepke CE, Wallace BC, Allen LA, et al.

    Circulation. Cardiovascular quality and outcomes 2022; (15(11)):e009352 doi:10.1161/CIRCOUTCOMES.122.009352.

    PMID: 36378770

This page explains HCM risk factors and ICD guidelines for educational purposes only. Always discuss your specific risk profile and device options with your cardiologist.

Get notified when new evidence is published on Hypertrophic Cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.